



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Leonard van den Berg**

Organisation/Company: University Medical Center Utrecht

Country: Netherlands

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
03/2016-(current)	Treeway	Edaravone	ALS
01/2018-(current)	MT Pharma	Edaravone	ALS
01/2016-(current)	Shire	IQvia	multifocal motor neuropathy
09/2020-(current)	Amylyx	AMX0035	ALS
09/2022-(current)	VectorY	consultant	
07/2022-(current)	Nevrargenics	consultant	
01/2023-(current)	Samsara	constultant	

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
01/2018-01/2020	ORION	levosimendan	ALS
01/2017-12/2018	Cytokinetics	CK-2127107	ALS

Classified as public by the European Medicines Agency

09/2020-(current)	Amylyx	AMX0035	ALS
09/2022-(current)	Biogen	Advisor	
11/2022-(current)	Zambon	advisor	
09/2022-(current)	Vectory	advisor	
01/2023-(current)	Takeda	advisor	
09/2022-(current)	Sanofi	advisor	
01/2023-(current)	Novartis	advisor	
09/2022-(current)	Biogen	advisor	

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2019-06/2021	Orphazyme	arimoclomol	ALS
01/2018-12/2020	orion	levosimendan	ALS
07/2021-(current)	Ferrer	FNP122	ALS
07/2021-(current)	Amylyx	AMX0035	ALS
06/2022-(current)	Corcept	dazucorilant	ALS
11/2021-(current)	Cytokinetics	Reldesemtiv	ALS
11/2022-(current)	IONIS	ION363	ALS
05/2018-(current)	Humanitas	TUDCA	ALS
11/2020-(current)	Biogen	BIIB105	ALS
06/2021-(current)	Wave Life Sciences	WVE-004	ALS
05/2022-(current)	Sanofi	RIPK1	ALS
11/2021-(current)	Apellis	Pegcetacoplan	ALS
11/2021-(current)	Denali	DNL343	ALS

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Shire	MMN Masterclass, unrestricted grant for non-inferiority study KIOVIG vs IQvia

3

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

I work together with Kings College London and Macquarie University on the Lighthouse II trial for ALS as an investigatory initiated trial to investigate Triumeq

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Classified as public by the European Medicines Agency

Full Name:	Leonard van den Berg
Date:	2023-01-27

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template